SK biopharmaceuticals Co., Ltd.

326030KOSPIResearch and development

SK biopharmaceuticals Co., Ltd. (326030, KOSPI) — reported financials from Korean regulatory filings.

Broker research: target prices and ratings

7 reports from 5 firms between 2026-08-27 and 2026-10-21. Taking the latest stated target from each of 4 firms, target prices range from KRW 155,000 to KRW 160,000; the median is KRW 160,000.

Newest first. Ratings are as each firm stated them, translated into English. "Not stated" means the report carried no value — it is not a zero.

DateTarget priceRatingFirmAnalyst
KRW 155,000BuyDS Investment & SecuritiesNot stated
KRW 160,000BuyHana SecuritiesNot stated
KRW 160,000BuyMirae Asset SecuritiesKim Seung-min
Not statedNot statedKiwoom SecuritiesNot stated
KRW 160,000BuySK SecuritiesLee Seon-gyeong
KRW 160,000BuyHana SecuritiesNot stated
KRW 155,000BuyDS Investment & SecuritiesNot stated

Analyst names are our Roman spellings of the Korean names on the listing; the analyst may spell their name differently. Where the listing gave no name, we took it from Hankyung Consensus only when the date, firm and ticker pointed to exactly one report.

Report titles are not shown: the source lists them in Korean only, and we do not publish our own translation of another firm's headline.

This is a record of what brokers published, not investment advice. It is a sample of broker research — the reports our collection picked up, not every report written on this company — and the range and median describe that sample, not a market consensus. These are statistics, not a verdict.

Source: broker reports collected by SeoulMarkets from Naver Finance's research listing and from brokers' own websites, 2026-06-29 to 2026-10-28.

Compare target prices across Korean biotech and pharma stocks →

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20214199565644444Consolidated
2022246-131-139664317Consolidated
2023355-38-35723321Consolidated
2024548962271,037574Consolidated
2025——————

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
202122.7%15.5%69%14.6%
2022-53.2%-56.6%47.7%-44%
2023-10.6%-10%44.4%-11%
202417.6%41.4%55.4%39.5%
2025————

Revenue moved 30.8% between 2021 and 2025.

Net profit was positive in the 1 most recent year on file. Counted from the 4 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 6,563bn
Close priceKRW 83,800
Listed shares78,313,250
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Lee Dong-hun (이동훈)Representative Director (CEO)Inside director6 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)272
Women136 (50%)
Average tenure6.3 years
Annual pay, menKRW 121,000,000
Annual pay, womenKRW 97,000,000
Pay ratio, women to men80.2%

Other companies in Research and development

63 listed companies file under this classification. Showing 12.

See the whole Research and development list →